DoD Prostate Cancer, Idea Development Award | W81XWH 18 PCRP IDA

Opportunity Information: Apply for W81XWH 18 PCRP IDA

The DoD Prostate Cancer Research Program (PCRP) Idea Development Award is a discretionary research funding opportunity designed to spark genuinely new, high-risk/high-reward ideas in prostate cancer. Its core purpose is to fund innovative concepts that could meaningfully move the field forward and align with the PCRP mission, rather than supporting routine extensions of already-published work. Projects are expected to offer a fresh angle, such as introducing a new research paradigm, challenging standard assumptions, applying unconventional methods, or leveraging unique patient populations or datasets. Multidisciplinary approaches are explicitly encouraged, and proposals that simply represent incremental progress on existing findings are not considered responsive to the program’s emphasis on innovation.

A central requirement is impact. Applications must directly address at least one of the PCRP Overarching Challenges and make a clear case for how the proposed work could deliver a concrete solution or advance toward one. Reviewers are looking for a strong, well-articulated pathway to meaningful outcomes, both in the near term and longer term, including the potential to substantially advance prostate cancer research and/or improve patient care if the project succeeds. In other words, novelty alone is not enough; the application has to convincingly argue that the idea, if validated, would matter.

Preliminary data are encouraged but not required, reflecting the award’s intent to make room for bold, earlier-stage concepts. When preliminary results are included, they should come from the Principal Investigator’s lab or from members of the research team and can be unpublished. Whether or not data are provided, proposals must still be built on a sound scientific rationale grounded in logical reasoning and a critical, well-supported reading of the existing literature.

The announcement also pushes applicants to design studies in ways that increase credibility and translational relevance. Suggested elements include authenticating cell lines, applying statistical rigor in preclinical animal studies and epidemiological analyses, and adding experiments that test clinical relevance and translatability, including validation in patient cohorts where appropriate. To support this, the program highlights established resources such as the PCRP-funded Prostate Cancer Biorepository Network (PCBN) and the North Carolina to Louisiana Prostate Cancer Project (PCaP) as options when retrospective human specimens or linked clinical data are important. The opportunity is also friendly to projects that mine large patient datasets with long-term health records and biospecimens, especially when paired with modern genomics/proteomics, bioinformatics, or mathematical modeling.

A notable feature is the New Investigator category, which is intended to help early-career researchers compete separately from established investigators. Eligible New Investigators (as defined by the program’s specific criteria) must include at least one collaborator with demonstrated prostate cancer research experience, evidenced through prior funding and publications. The application needs to explain how the collaboration fills gaps in expertise and strengthens the overall ability of the team to answer the research question.

Team science is a clear priority. Multidisciplinary and multi-institutional projects are allowed, but they must include a concrete management plan describing how collaborators will communicate, coordinate progress, share results, and transfer data. If multiple institutions are involved, applicants also have to provide an intellectual property plan to prevent ownership or material-transfer disputes from undermining cooperation or slowing the work.

Human subjects research is allowed, but clinical trials are not. The program draws a firm line: studies can involve human participants or human-derived materials as long as they are not prospective intervention trials. Correlative studies tied to an existing clinical trial are particularly encouraged if they are determined to be no greater than minimal risk by the relevant Institutional Review Board and by the USAMRMC Office of Research Protections/Human Research Protection Office. For investigators seeking to run an actual clinical trial, the announcement points them toward a different PCRP mechanism (the Impact Award).

From a practical funding standpoint, the FY18 Idea Development Award anticipates direct costs up to $600,000 for the entire period of performance. Awards are made as assistance agreements, either as grants or cooperative agreements. Which one is used depends on how much involvement the DoD expects to have during the project: a grant is used when substantial agency involvement is not anticipated, while a cooperative agreement is used when the DoD anticipates substantial involvement such as collaboration or active participation, with those expectations spelled out during negotiation.

Administratively, the opportunity is run by the Department of Defense, Department of the Army (USAMRAA). It is listed under Funding Opportunity Number W81XWH-18-PCRP-IDA, falls under CFDA 12.420, and is broadly open to eligible applicant organizations (unrestricted by entity type, subject to any specific clarifications in the full announcement). The research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the broader American public. The original FY18 posting lists an expected 42 awards, with a creation date of May 21, 2018 and an original closing date of September 27, 2018.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 21, 2018.
• Applicants must submit their applications by Sep 27, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 42 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 18 PCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: